Lv1
89 积分 2024-09-29 加入
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
13小时前
待确认
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
2个月前
已完结
Cancer-related coagulopathies
2个月前
已完结
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
4个月前
已完结
Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial
4个月前
已完结
Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists
4个月前
已完结
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study
6个月前
已完结
Profound response to venetoclax monotherapy in a patient with BCL-2 positive relapsed multiple myeloma and extramedullary CNS manifestations
7个月前
已完结
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression
7个月前
已完结
Combination therapy incorporating Bcl‐2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
7个月前
已完结
皖公网安备34019202002308
